Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SFRT Combined With PraG Strategy for Soft Tissue Sarcoma
NCT07342322Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Feb 2026
- Primary completion
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in soft tissue sarcoma (STS), sponsored by The First Affiliated Hospital of Guangxi Medical University. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07342322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07342322.